Neem's Hill AB
NEEMS-B.ST
Stockholm Stock Exchange2.71
SEK
-0.05
- -
ISIN
SE0009242654
Return %
Stock
S&P500
1Y
-58.31
15.01
3Y
-2.52
82.56
5Y
-86.81
79.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Stefan Mohan Frick
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Medicon Village Lund SN Sweden 223 63
- IPO Date
- Dec 6, 2016
- Website
- chemotech.se
- Similar Companies
- Business
- Neem’s Hill AB is a medical technology company that develops and commercializes patented tumour-specific electroporation technology for cancer treatment in humans and animals; its core offerings include the IQwave™ platform, TSE-based treatment systems, advanced hardware and software, and related clinical and commercial support services for superficial solid tumours and other hard-to-treat cancers. The company operates through two business areas, Human Care and Animal Care, and focuses on cost-effective, tissue-preserving therapies that complement or reduce reliance on surgery, radiotherapy, and chemotherapy, with geographic emphasis on Sweden and international markets including India and selected regions in the Middle East, Asia, Southeast Asia, Africa, and veterinary markets across Europe and other regions. Founded in 2013 and headquartered in Lund, Sweden, Neem’s Hill AB was formerly Scandinavian ChemoTech AB and changed its name and trading ticker to reflect a broader strategic scope. Recent major developments include a strategic reorganization into separate Human Care and Animal Care business areas, a SEK 6 million growth loan to support commercial expansion, and a strategic partnership plus order from the University of Copenhagen’s veterinary hospitals to expand VQ Animal Care’s TSE treatment into companion animal and equine clinical settings. The company has also reported continued clinical progress in veterinary oncology, including publications and treatment outcomes supporting its Animal Care business, while maintaining its focus on patented TSE technology and broader commercialization of tumour-specific electroporation solutions.